MX2012001263A - Metodo para purificar adamts13 recombinante y otras proteinas y sus composiciones. - Google Patents

Metodo para purificar adamts13 recombinante y otras proteinas y sus composiciones.

Info

Publication number
MX2012001263A
MX2012001263A MX2012001263A MX2012001263A MX2012001263A MX 2012001263 A MX2012001263 A MX 2012001263A MX 2012001263 A MX2012001263 A MX 2012001263A MX 2012001263 A MX2012001263 A MX 2012001263A MX 2012001263 A MX2012001263 A MX 2012001263A
Authority
MX
Mexico
Prior art keywords
protein
adamts13
methods
compositions
sample
Prior art date
Application number
MX2012001263A
Other languages
English (en)
Inventor
Artur Mitterer
Meinhard Hasslacher
Christa Mayer
Christian Fiedler
Original Assignee
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare Sa filed Critical Baxter Healthcare Sa
Publication of MX2012001263A publication Critical patent/MX2012001263A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/12—Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/14—Enzymes or microbial cells immobilised on or in an inorganic carrier
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/06—Inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Sustainable Development (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Water Supply & Treatment (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente proporciona métodos para purificar un tipo de Disintegrina A y metalopeptidasa con proteína de Motivo 13 de Tipo 1 de Tromboespondina (ADAMTS13) a partir de una muestra. El método comprende enriquecer la proteína ADAMTS13 poniendo en contacto cromatográficamente la muestra con hidroxiapatita bajo condiciones que permiten que la proteína ADAMTS13 aparezca en el producto eluido o sobrenadante de la hidroxilapatita. Los métodos además comprenden cromatografía en tándem con una resma de intercambio de catión de modo mixto/de interacción hidrofóbica que une la proteína ADAMTS13. Pasos opcionales adicionales involucran ultrafiltración/diafiltración, cromatografía de intercambio de anión, cromatografía de intercambio de catión, e inactivación viral. También se proporcionan aquí métodos para inactivar contaminantes de virus en muestras de proteínas, en donde la proteína es inmovilizada sobre un soporte. También la presente proporciona composiciones de ADAMTS13 preparadas de acuerdo con dichos métodos.
MX2012001263A 2009-07-31 2010-08-02 Metodo para purificar adamts13 recombinante y otras proteinas y sus composiciones. MX2012001263A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23030809P 2009-07-31 2009-07-31
PCT/EP2010/061192 WO2011012726A2 (en) 2009-07-31 2010-08-02 Method for purifying recombinant adamts13 and other proteins and compositions thereof

Publications (1)

Publication Number Publication Date
MX2012001263A true MX2012001263A (es) 2012-05-22

Family

ID=42588355

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012001263A MX2012001263A (es) 2009-07-31 2010-08-02 Metodo para purificar adamts13 recombinante y otras proteinas y sus composiciones.
MX2014008412A MX348178B (es) 2009-07-31 2010-08-02 Método para purificar adamts13 recombinante y otras proteínas y sus composiciones.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2014008412A MX348178B (es) 2009-07-31 2010-08-02 Método para purificar adamts13 recombinante y otras proteínas y sus composiciones.

Country Status (23)

Country Link
US (3) US8945895B2 (es)
EP (3) EP2459715B1 (es)
JP (6) JP5907869B2 (es)
KR (7) KR20190122272A (es)
CN (3) CN107988192A (es)
AU (1) AU2010277491B2 (es)
BR (1) BR112012002140A2 (es)
CA (2) CA2769362A1 (es)
CO (1) CO6612194A2 (es)
DK (1) DK2459715T3 (es)
EA (3) EA201992487A1 (es)
ES (1) ES2763207T3 (es)
HR (1) HRP20192303T1 (es)
HU (1) HUE046909T2 (es)
IN (1) IN2012DN00907A (es)
LT (1) LT2459715T (es)
MX (2) MX2012001263A (es)
NZ (2) NZ620988A (es)
PL (1) PL2459715T3 (es)
PT (1) PT2459715T (es)
SG (2) SG178175A1 (es)
SI (1) SI2459715T1 (es)
WO (1) WO2011012726A2 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481693B2 (en) 2007-03-14 2013-07-09 Takeda Vaccines (Montana), Inc. Virus like particle purification
FR2918375B1 (fr) * 2007-07-05 2009-10-16 Lab Francais Du Fractionnement Utilisation d'un support de chromatographie pour reduire la quantite d'adamts13 dans une solution derivee du plasma
WO2012125626A2 (en) * 2011-03-14 2012-09-20 Catalent Pharma Solutions Llc Decorin compositions and use thereof
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2013028330A2 (en) * 2011-08-19 2013-02-28 Emd Millipore Corporation Methods of reducing level of one of more impurities in a sample during protein purification
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
MY195362A (en) * 2012-06-21 2023-01-16 Baxalta Inc Virus Filtration of Cell Culture Media
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
AU2013309506A1 (en) 2012-09-02 2015-03-12 Abbvie Inc. Methods to control protein heterogeneity
ES2768261T3 (es) * 2013-01-09 2020-06-22 Shire Human Genetic Therapies Métodos para la purificación se arilsulfatasa A
AU2013381687A1 (en) 2013-03-12 2015-09-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) * 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US8859252B1 (en) 2014-01-02 2014-10-14 Aerial Biopharma, Llc Prostatic acid phosphatase, compositions comprising the same, and methods for producing and/or purifying the same
KR102567586B1 (ko) * 2014-02-04 2023-08-16 바이오젠 엠에이 인코포레이티드 번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도
BR112019002194A2 (pt) 2016-08-04 2019-05-21 Baxalta GmbH uso de adamts13 para tratar, melhorar e/ou prevenir a crise vaso-oclusiva na doença falciforme, lesão pulmonar aguda e/ou síndrome da insuficiência respiratória aguda
WO2019192877A1 (en) * 2018-04-03 2019-10-10 Merck Patent Gmbh Cex chromatography media and low salt elution of target proteins from biopharmaceutical feeds
KR102140531B1 (ko) * 2018-08-07 2020-08-04 (주)휴온스 Gly-Tβ4의 제조방법
KR20210149117A (ko) * 2019-04-03 2021-12-08 젠자임 코포레이션 재조합 단백질의 연속 생산
US11821000B2 (en) * 2020-11-10 2023-11-21 Dionex Corporation Method of separating viral vectors
WO2023052556A1 (en) * 2021-09-30 2023-04-06 Ichnos Sciences SA Methods of inactivating viral contaminants with a mixture of solvent and detergent
WO2023170553A1 (en) 2022-03-07 2023-09-14 Takeda Pharmaceutical Company Limited Affinity chromatographic production of clinical human igg products
TW202400224A (zh) * 2022-05-10 2024-01-01 南韓商綠十字股份有限公司 用於冷凍乾燥血漿蛋白之新穎液體調配物
TW202400238A (zh) * 2022-05-10 2024-01-01 南韓商綠十字股份有限公司 血漿蛋白之新穎液體調配物

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4239854A (en) * 1978-04-24 1980-12-16 Sumitomo Chemical Company, Limited Enzyme-immobilization carriers and preparation thereof
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US5283182A (en) * 1986-09-17 1994-02-01 Beecham Group Plc Preparation of immobilized hydantoinase stabilized with divalent metal ions
CA1339946C (en) * 1987-03-31 1998-07-07 Michael J. Griffith Ultrapurification process for polypeptides
US5792835A (en) * 1991-09-05 1998-08-11 Baxter International Inc. Method of preparing a topical fibrinogen complex
FR2681867B1 (fr) 1991-09-26 1993-12-31 Pasteur Merieux Serums Vaccins Procede de purification du facteur viii et preparations obtenues.
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
EP0629135B1 (en) 1992-03-02 2000-07-26 Bioeng, Inc. Viral inactivation method
US5296228A (en) * 1992-03-13 1994-03-22 Allergan, Inc. Compositions for controlled delivery of pharmaceutical compounds
US5288853A (en) 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
US5578480A (en) * 1993-04-23 1996-11-26 American Cyanamid Company Methods for the isolation and purification of the recombinantly expressed chondroitinase I and II enzymes from P. vulgaris
GB9503750D0 (en) * 1995-02-24 1995-04-12 Common Services Agency Thrombin preparation
US5688912A (en) 1995-09-22 1997-11-18 Bayer Corporation Peptide ligands which bind to von willebrand factor
US5786458A (en) * 1996-06-28 1998-07-28 Bayer Corporation Selective stabilization of protein during viral inactivation
US5831003A (en) 1996-06-28 1998-11-03 Bayer Corporation Peptides which bind to prothrombin and thrombin
US7141393B2 (en) * 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
US6429192B1 (en) 1998-06-10 2002-08-06 Statens Serum Institut Purification process for production of mannan-binding lectin and an MBL medicinal product
US6251860B1 (en) * 1998-07-07 2001-06-26 Suomen Punainen Risti Veripalvelu Pharmaceutical preparations
US6214221B1 (en) 1999-02-22 2001-04-10 Henry B. Kopf Method and apparatus for purification of biological substances
US6451978B2 (en) * 2000-01-21 2002-09-17 Biovitrum Ab Purification of antithrombin-III-α and β
IL136552A (en) * 2000-06-05 2005-05-17 Omrix Biopharmaceuticals Ltd Method for the inactivation of viruses by a solvent - detergent combination and by nanofiltration
JPWO2002031163A1 (ja) * 2000-10-11 2004-02-19 財団法人かずさディー・エヌ・エー研究所 新規なａｄａｍｔｓファミリーポリペプチドおよびそれをコードする遺伝子
US6926894B2 (en) 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
CN1230526C (zh) * 2001-02-27 2005-12-07 成都夸常科技有限公司 一种除去作为病毒灭活剂的有机溶剂和/或去污剂的方法
WO2003016492A2 (en) 2001-08-16 2003-02-27 The Regents Of The University Of Michigan Adamts13 genes and proteins and variants, and uses thereof
JP2003144154A (ja) * 2001-11-14 2003-05-20 Mitsubishi Pharma Corp 新規なａｄａｍｔｓファミリーポリペプチドおよびそれをコードする遺伝子
IL158297A0 (en) * 2001-12-05 2004-05-12 Cangene Corp Pharmaceutical compositions containing immune globulin and methods for the preparation thereof
DE60231651D1 (de) 2001-12-21 2009-04-30 Immunex Corp Proteinreinigungsverfahren
US20030133829A1 (en) * 2001-12-21 2003-07-17 Baxter Healthcare Corporation Process for inactivating pathogens in a biological material
GB0216002D0 (en) * 2002-07-10 2002-08-21 Nat Blood Authority Process and composition
GB0216001D0 (en) 2002-07-10 2002-08-21 Nat Blood Authority Process and composition
JP3944586B2 (ja) * 2002-10-18 2007-07-11 国立循環器病センター総長 フォンビルブランド因子切断酵素の特異的基質および活性測定法
CA2487673C (en) * 2003-12-02 2010-11-02 F. Hoffmann-La Roche Ag Improved method for the recombinant production and purification of protein kinases
GB0405330D0 (en) * 2004-03-10 2004-04-21 Astrazeneca Ab Enzyme and preparation method
WO2005099858A1 (en) * 2004-04-13 2005-10-27 Sangart, Inc. Methods and compositions for simultaneously isolating hemoglobin from red blood cells and inactivating viruses
DK1765866T3 (en) 2004-06-07 2014-03-24 Therapure Biopharma Inc ISOLATION OF plasma or serum protein
US7270976B2 (en) 2004-07-19 2007-09-18 American Diagnostica, Inc. Methods for measuring ADAMTS13 activity and protein on platelets and in plasma
DE102004044419B4 (de) * 2004-09-14 2010-04-15 Biotest Ag Verfahren zur Aufreinigung eines von Willebrand Faktors mittels Hydroxylapatit-Durchlaufchromatographie
CA2592888A1 (en) * 2005-01-05 2006-07-13 Foundation For Fatal Rare Diseases Pharmaceutically active antiviral peptides
US20060193966A1 (en) * 2005-02-28 2006-08-31 Shaowen Wu Multi-anion treated soy proteins and methods for preparation thereof
ATE544866T1 (de) 2005-06-17 2012-02-15 Baxter Int Adamts13-haltige zusammensetzungen mit thrombolytischer wirkung
FR2887883B1 (fr) 2005-06-29 2007-08-31 Lab Francais Du Fractionnement Procede de separation des proteines fibrinogene, facteur xiii et colle biologique d'une fraction plasmatique solubilisee et de preparation de concentres lyophilises desdites proteines
CN101379077A (zh) * 2005-12-07 2009-03-04 夏洛特·豪泽 因子ⅷ和因子ⅷ-类似蛋白的小肽或者拟肽亲合性配体
JP5067917B2 (ja) 2005-12-28 2012-11-07 アルフレッサファーマ株式会社 Ａｄａｍｔｓ１３の分離精製方法
KR101366724B1 (ko) 2006-02-16 2014-02-25 미쓰비시 가가쿠 메디엔스 가부시키가이샤 의식장애환자의 병태 검출방법 및 검출용 키트
US7468258B2 (en) 2006-03-07 2008-12-23 Wake Forest University Health Sciences Self-quenching homofluorophore compositions for detecting enzyme activity
WO2008057074A1 (en) * 2006-11-06 2008-05-15 Millipore Corporation Method of flow-through chromatography
JP5505853B2 (ja) 2007-02-13 2014-05-28 味の素株式会社 微酸性アルギニンを添加剤とするウイルス不活化法
WO2009001743A1 (ja) * 2007-06-22 2008-12-31 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute 新規adamts-13改変体
FR2918375B1 (fr) * 2007-07-05 2009-10-16 Lab Francais Du Fractionnement Utilisation d'un support de chromatographie pour reduire la quantite d'adamts13 dans une solution derivee du plasma
JP5323072B2 (ja) 2007-07-11 2013-10-23 ノボ・ノルデイスク・エー／エス 混合方式又は多様式樹脂を使用する第ｖｉｉｉ因子の精製
JP5570989B2 (ja) * 2007-08-31 2014-08-13 アムジエン・インコーポレーテツド 固体タンパク質製剤
US20090130714A1 (en) * 2007-09-24 2009-05-21 Reliance Life Sciences Pvt.Ltd. Process for purifying recombinanat tissue plasminogen activator (TPA)

Also Published As

Publication number Publication date
CN107267490A (zh) 2017-10-20
AU2010277491A1 (en) 2012-02-16
KR101769634B1 (ko) 2017-08-18
JP6216930B2 (ja) 2017-10-25
EA023783B1 (ru) 2016-07-29
SG178175A1 (en) 2012-03-29
LT2459715T (lt) 2020-01-10
WO2011012726A2 (en) 2011-02-03
KR20180087463A (ko) 2018-08-01
CA2769362A1 (en) 2011-02-03
EA201992487A1 (ru) 2020-05-31
DK2459715T3 (da) 2020-01-06
JP2013500711A (ja) 2013-01-10
EP4299735A3 (en) 2024-04-24
KR20200146042A (ko) 2020-12-31
US11661593B2 (en) 2023-05-30
AU2010277491B2 (en) 2015-12-17
KR101883610B1 (ko) 2018-07-30
CO6612194A2 (es) 2013-02-01
EP4299735A2 (en) 2024-01-03
US20110081700A1 (en) 2011-04-07
EA201270214A1 (ru) 2012-08-30
BR112012002140A2 (pt) 2015-09-15
HUE046909T2 (hu) 2020-04-28
EP3211077A1 (en) 2017-08-30
WO2011012726A3 (en) 2011-03-31
SG193855A1 (en) 2013-10-30
AU2010277491A2 (en) 2012-06-21
ES2763207T3 (es) 2020-05-27
MX348178B (es) 2017-05-29
US20150104849A1 (en) 2015-04-16
HRP20192303T1 (hr) 2020-10-02
PT2459715T (pt) 2020-01-09
EA034292B1 (ru) 2020-01-24
JP2022171925A (ja) 2022-11-11
JP5907869B2 (ja) 2016-04-26
JP2018203781A (ja) 2018-12-27
US20230242897A1 (en) 2023-08-03
NZ597756A (en) 2014-03-28
EP2459715A2 (en) 2012-06-06
KR20120053013A (ko) 2012-05-24
KR20170096061A (ko) 2017-08-23
NZ620988A (en) 2015-07-31
IN2012DN00907A (es) 2015-04-03
KR20190122272A (ko) 2019-10-29
JP2015147815A (ja) 2015-08-20
CN107988192A (zh) 2018-05-04
CN102482660A (zh) 2012-05-30
EP2459715B1 (en) 2019-10-02
JP2016222724A (ja) 2016-12-28
US8945895B2 (en) 2015-02-03
SI2459715T1 (sl) 2020-01-31
CA2916508A1 (en) 2011-02-03
EA201500952A1 (ru) 2016-05-31
PL2459715T3 (pl) 2020-04-30
KR20220066435A (ko) 2022-05-24
KR20230170815A (ko) 2023-12-19
JP2021004265A (ja) 2021-01-14

Similar Documents

Publication Publication Date Title
MX348178B (es) Método para purificar adamts13 recombinante y otras proteínas y sus composiciones.
MX2018014395A (es) Aislamiento y purificacion de anticuerpos usando la cromatografia de afinidad de proteina a.
MX2012004711A (es) Aislamiento y purificacion de los anticuerpos anti-il-13 al usar cromatografia de afinidad con proteina a.
CA2551345C (fr) Procede de separation des proteines fibrinogenes, facteur xiii et colle biologique d'une fraction plasmatique solubilisee et de preparation de concentres lyophilises desdites proteines
WO2006041934A3 (en) Methods and compositions for improving recombinant protein production
JP2013500711A5 (es)
RU2011137030A (ru) Способы очистки малых модулярных иммунофармацевтических белков
MX2020003798A (es) Metodos para la purificacion de arilsulfatasa a.
AR074015A1 (es) Purificacion de proteinas acidas utilizando cromatografia de hidroxiapatita ceramica
PE20150720A1 (es) Purificacion de iduronato-2-sulfatasa
WO2006113475A3 (en) Methods and compositions to modulate adhesion and stress tolerance in bacteria
SG157346A1 (en) Improved purification of collagenases from clostridium histolyticum liquid culture
WO2012024400A3 (en) Elution of proteins from hydroxyapatite resins without resin deterioration
NZ781138A (en) Anti-vegf protein compositions and methods for producing the same
DE69435020D1 (en) Protein-tyrosin-phosphatase ptp-s31
Piazza et al. Identification of highly active flocculant proteins in bovine blood
WO2006091535A3 (en) Novel egg receptors for sperm proteins
MX2022001166A (es) Metodo para inactivacion viral.
ATE496133T1 (de) Affinitätspolypeptid zur reinigung von rekombinanten proteinen
ATE553194T1 (de) Verfahren zur dipeptidherstellung
JP2015156821A (ja) ヒト膵臓特異的リボヌクレアーゼ１及びその分離方法
AU2014230101B2 (en) Purification method for vitamin K dependent proteins by anion exchange chromatography
DE602007012759D1 (en) Regaten therapeutischer proteine
WO2006032781A3 (fr) Derives peptidiques , compositions et utilisations dans un traitement therapeutique de l’infection par un herpevirus

Legal Events

Date Code Title Description
FG Grant or registration